Intestinal
commensal
microbes,
called
the
gut
microbiota,
play
a
critical
role
in
host
immune
homeostasis
through
active
microbial
metabolites
and
innate
adaptive
responses.
Dysbiosis
or
imbalance
of
microbiota
composition
is
associated
with
inflammatory
bowel
disease
(IBD)
which
includes
Crohn’s
ulcerative
colitis.
The
incidence
prevalence
rates
IBD
have
been
increasing
worldwide.
It
well
recognized
that
butyrate,
metabolite
diet
fibers,
major
energy
source
for
colonocytes
plays
crucial
regulating
function
maintaining
epithelial
barrier
intestinal
homeostasis.
Emerging
evidence
suggests
butyrate
might
be
potential
therapeutic
agent
to
treat
IBD.
In
this
review,
we
discuss
about
metabolites,
particularly
synthesis
metabolism
mechanisms
function.
Furthermore,
review
current
research
on
various
implications
Food Frontiers,
Journal Year:
2023,
Volume and Issue:
4(3), P. 1462 - 1471
Published: June 3, 2023
Abstract
Polysaccharides
are
typically
resistant
to
digestion
in
the
gastrointestinal
tract
and
instead
degraded
by
gut
microbiota
colon.
As
such,
they
commonly
employed
as
carriers
for
colon‐targeted
drugs,
with
potential
regulate
microbiota.
Pectin,
carrageenan,
guar
gum,
xanthan
gum
used
polysaccharide
carriers,
but
their
degradation
under
colitis
conditions
well
effects
on
remains
unclear.
In
this
study,
we
performed
vitro
fermentation
of
these
four
polysaccharides
using
colonic
content
from
mice
evaluated
degree
pH,
short‐chain
fatty
acids,
Our
findings
indicate
that
pectin
had
a
greater
promoted
production
butyrate,
inhibited
proliferation
harmful
bacteria
(e.g.,
Enterobacteriaceae
),
increased
beneficial
Bifidobacterium
).
contrast,
carrageenan
promote
.
These
results
provide
theoretical
guidance
selection
drug
delivery
inflammatory
bowel
disease
treatment
information
relationship
between
Chemical Society Reviews,
Journal Year:
2024,
Volume and Issue:
53(4), P. 1789 - 1822
Published: Jan. 1, 2024
This
review
discusses
the
balance
of
inflammation
in
immunity
and
biomaterials
strategies
to
modulate
cases
imbalance
such
as
autoimmune
disease,
infection,
cancer.
Adapted
from
“Balanced
Energy
State”,
by
BioRender.com
(2023).
Nature Biomedical Engineering,
Journal Year:
2024,
Volume and Issue:
8(5), P. 611 - 627
Published: April 1, 2024
Butyrate-a
metabolite
produced
by
commensal
bacteria-has
been
extensively
studied
for
its
immunomodulatory
effects
on
immune
cells,
including
regulatory
T
macrophages
and
dendritic
cells.
However,
the
development
of
butyrate
as
a
drug
has
hindered
butyrate's
poor
oral
bioavailability,
owing
to
rapid
metabolism
in
gut,
low
potency
(hence,
necessitating
high
dosing),
foul
smell
taste.
Here
we
report
that
bioavailability
can
be
increased
esterifying
it
serine,
an
amino
acid
transporter
aids
escape
resulting
odourless
tasteless
prodrug
(O-butyryl-L-serine,
which
named
SerBut)
from
enhancing
systemic
uptake.
In
mice
with
collagen-antibody-induced
arthritis
(a
model
rheumatoid
arthritis)
experimental
autoimmune
encephalomyelitis
multiple
sclerosis),
show
SerBut
substantially
ameliorated
disease
severity,
modulated
key
cell
populations
systemically
disease-associated
tissues,
reduced
inflammatory
responses
without
compromising
global
response
vaccination.
may
become
promising
therapeutic
diseases.
Acta Pharmaceutica Sinica B,
Journal Year:
2024,
Volume and Issue:
14(5), P. 2153 - 2176
Published: Feb. 29, 2024
Aberrant
changes
in
the
gut
microbiota
are
implicated
many
diseases,
including
inflammatory
bowel
disease
(IBD).
Gut
microbes
produce
diverse
metabolites
that
can
shape
immune
system
and
impact
intestinal
barrier
integrity,
indicating
microbe-mediated
modulation
may
be
a
promising
strategy
for
preventing
treating
IBD.
Although
fecal
transplantation
probiotic
supplementation
well-established
IBD
therapies,
novel
chemical
agents
safe
exert
strong
effects
on
urgently
needed.
Herein,
we
report
total
synthesis
of
heudelotinone
discovery
5
The Journal of Immunology,
Journal Year:
2024,
Volume and Issue:
212(2), P. 208 - 215
Published: Jan. 2, 2024
Abstract
The
gut
microbiota,
predominantly
residing
in
the
colon,
is
a
complex
ecosystem
with
pivotal
role
host
immune
system.
Dysbiosis
of
microbiota
has
been
associated
various
diseases,
and
there
an
urgent
need
to
develop
new
therapeutics
that
target
microbiome
restore
functions.
This
Brief
Review
discusses
emerging
therapeutic
strategies
focus
on
oral
delivery
systems
for
modulating
microbiome.
These
include
genetic
engineering
probiotics,
probiotic-biomaterial
hybrids,
dietary
fibers,
microbial
metabolites,
antimicrobial
peptides,
RNA,
antibiotics.
Engineered
formulations
have
demonstrated
promising
outcomes
reshaping
influencing
responses
preclinical
studies.
By
leveraging
these
approaches,
interplay
between
system
can
be
harnessed
development
novel
against
cancer,
autoimmune
disorders,
allergies.
